Osteoporosis Therapeutics In Asia-Pacific Markets will be valued at $7.7 billion in 2022

The report analysis, new study and presents an overview on “Osteoporosis Therapeutics In Asia-Pacific Markets To 2022″ worldwide.

Osteoporosis, the most common metabolic bone disease, is characterized by low bone mass, microarchitectural deterioration of bone tissue, and a consequent increase in fracture risk. Osteoporosis is generally known as an asymptomatic disease, as there are no visible signs until a fracture occur. In most of the cases, fracture is the clinical outcome associated with osteoporosis, and it has a complex pathogenesis that involves trauma to the bone and increased skeletal fragility. Osteoporosis is a major global public health problem, associated with significant morbidity, mortality, and socioeconomic burden. An aging global population will result in an increased number of people living with the condition, thereby acting as a driver for revenue growth.

The osteoporosis market is undergoing a gradual transition from a focus on antiresorptive therapies to anabolic drug treatment. The market is set to be driven by recently launched products, and the approval of drugs that will supplement current market leaders and offer greater therapeutic options. The marketed products landscape comprises a wide range of treatment options, including bisphosphonates, SERMs, RANKL inhibitors, a dual-action non-bisphosphonate (strontium ranelate), calcitonins and PTH analogues. Nevertheless, significant unmet need remains for products that can improve bone formation, as well as effective antiresorptive therapies that offer increased compliance with few side effects.

To Get The Sample Copy Of This Report: http://www.marketresearchreports.biz/sample/sample/784620

Scope

The osteoporosis Asia-Pacific market will be valued at $7.7 billion in 2022, growing from $4.5 billion in 2015 at a CAGR of 7.8%.

Bisphosphonates and SERMs dominate the osteoporosis market. However, unmet needs exist in terms of safety and efficacy. Will the drugs under development fulfill the unmet needs of the osteoporosis market?
How will immunotherapies such as Prolia contribute to growth?
What effect will the patent expirations of currently branded therapies have on market value?
The pipeline contains a range of molecule types and molecular targets, including those that are well established in osteoporosis, and novel, first-in-class therapies.

Which molecular targets appear most frequently in the pipeline?
Is there strong potential for the pipeline to address unmet needs within the osteoporosis market?
Will the pipeline address unmet needs related to limited anabolic therapies for osteoporosis patients?
The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value, due to the emergence of novel therapies.

How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?
How could changes in risk factors such as aging population, calcium and vitamin D deficiency influence the market?
Various drivers and barriers will influence the market over the forecast period.
What are the barriers that limit the uptake of premium-priced therapeutics in the assessed countries?
Which factors are most likely to drive the market in these countries?

Explore More Pharmaceutical Market Research Reports: http://www.marketresearchreports.biz/category/38

Reasons to buy

This report will allow you to –

Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
Visualize the composition of the osteoporosis market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.
Analyze the osteoporosis pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, – and how they will compete with other therapies.
Predict osteoporosis market growth in the five Asia-Pacific markets with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as individual contributions of promising late-stage molecules to market growth.
Identify commercial opportunities in the osteoporosis deals landscape by analyzing trends in licensing and co-development deals.

To View The Latest Industry Press Releases: http://www.marketresearchreports.biz/pressreleases

Global Peripheral Artery Disease (PAD) Market Research, Size, Forecast, Trends & Opportunities (2015-2020)

The report “Global Peripheral Artery Disease (PAD) Market Research”, has been prepared based on an in-depth market analysis with inputs from industry experts.

Scope of the Report

This report entitled Global Peripheral Artery Disease Market: Trends & Opportunities (2015-2020), analyses the global market for peripheral artery disease and the treatments available for it. The global peripheral artery disease market is analyzed by value, by number of people affected from PAD, PAD by prevalence, by treatment mix and by players in this market. This report also includes forecasting of peripheral artery disease market by value and by number of people affected for the years 2015-2020. The sizing and growth of global peripheral atherectomy market is provided in this report, which includes PAD atherectomy market by value and by players. The forecasting of PAD atherectomy market by value is also provided for the years 2015-2020.

This report includes the analysis of global peripheral artery disease device market by value and by product types. This segment of report also includes the sizing and growth of global PAD angioplasty market and global PAD stent market, with focus on drug coated balloons (DCB) market and drug eluting stents (DES) market.

Furthermore, this report also provides the analysis of United States peripheral artery disease market. The analysis includes the US PAD market by value and by treatment mix. This segment of report also includes the US PAD atherectomy market by value and by players and the US PAD drug coated balloons (DCB) market by value and by players.

To Get The Sample Copy Of This Report:http://www.marketresearchreports.biz/sample/sample/550827

Global peripheral artery disease market dynamics are also given in this report which includes the growth drivers, market trends and challenges faced by this market. Company profiling of three major players (Johnson & Johnson, Medtronic Inc. and Stryker Corporation) of peripheral artery disease market is done in this report. Company profiling includes business overview, financial overview and business strategies of each company.

Country Coverage

United States

Company Coverage

Johnson & Johnson
Medtronic Inc.
Stryker Corporation

Executive Summary

Peripheral artery disease (PAD) is a medical condition in which arteries become narrow due to build-up of plague on the vessel walls. Peripheral artery disease affects the arteries of arms, legs or neuro-vasculature, other than those that supply the heart and brain.

Peripheral artery disease is also known as Peripheral Vascular Disease (PVD) and Peripheral Artery Occlusive Disease. Plaque that deposits in the arteries is made up of fats, cholesterol, calcium, fibrous tissue and other substances in the blood. Plaque formations can grow large enough to significantly reduce the blood’s flow through an artery.

Treatment of Peripheral artery disease requires multiple approaches, depending on the individual patient. There are two main approaches for the treatment of PAD. The first approach is endovascular treatment, which includes stenting, ballooning and atherectomy. These different treatments can also be used in combination, such as atherectomy with stenting. The second approach is surgical treatment, which includes bypass surgery and amputation.

The global peripheral artery disease market has increased with a healthy growth rate in 2014 and is expected to increase further in coming years. The main driving forces for PAD market are increasing population, especially the age group of 65 and above, rising global healthcare expenditure, technological advancements and favorable reimbursement rates for PAD treatment. Yet there are some challenges which PAD industry faces such as restenosis (re-occurrence of PAD post treatment), inappropriate diagnosis and limitations of existing devices.

To View The Latest Industry Press Releases:http://www.marketresearchreports.biz/pressreleases

Global Urological Cancer Market Shares To 2022 – Strong Growth Driven By Rising Prevalence, Increased Uptake Of Hormone Therapies And Approval Of Novel Biologics

Worldwide Market studies the current scenario as well as future market potential of “Global Urological Cancer Market To 2022 – Strong Growth Driven By Rising Prevalence, Increased Uptake Of Hormone Therapies And Approval Of Novel Biologics”

Urological cancers are thought to account for 19.5% of global cancer prevalence, with kidney, prostate, testicular and bladder cancer – the key indications covered in this report – accounting for the majority of that figure. Urological cancers affect the male and female urinary tract and the male reproductive organs. Prostate cancer is the most prevalent of these malignancies.

A number of common etiologic factors have been strongly characterized as raising the risk of developing urological cancers, including age, chronic inflammation, gender, obesity, tobacco usage and heritable cancer syndromes. The risk of cancer increases greatly in patients over the age of 65. Populations in developed countries are projected to become increasingly aged and show rising obesity incidence, which will drive both cancer prevalence and revenue growth for its treatments.

Hormone therapies for prostate cancers and angiogenesis inhibitors for renal cell carcinoma are currently the most commercially successful urological cancer drugs. However, there has been a shift towards the clinical testing of cancer immunotherapies – such as Opdivo, which was recently approved for renal cell carcinoma. The forecast period will also witness the approval of a greater number of targeted therapies, which by their nature have less toxicity associated with their use, and as a result can be administered to patients with poor performance statuses, therefore increasing the overall survival of this group and the number of treatment cycles they may receive.

To Get The Sample Copy Of This Report: http://www.marketresearchreports.biz/sample/sample/759626

Scope

Global revenues for the urological cancer market are forecast to grow at a Compound Annual Growth Rate (CAGR) of 10.39%, from $17.9 billion in 2015 to $35.9 billion in 2022. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
The urologic oncology pipeline is large and diverse, and contains 817 products. How does the composition of the pipeline compare with that of the existing market?
What mechanisms of action and molecule types are most common for pipeline drugs being trialed in the various key indications?
How will the market shares and CAGRs of the top 20 companies compare within this therapy area?
What proportion of the key players’ revenues will be attributable to urological cancers?

Reasons to buy

This report will allow you to

Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis
Visualize the composition of the urological cancer market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
Analyze the urological cancer pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
Understand the growth in patient epidemiology and market revenues for the urological cancer market globally and across the key players and product types
Stratify the market in terms of the split between generic and premium products, and assess the role of these product types in the treatment of the various urological cancers
Identify commercial opportunities in the urological cancer deals landscape by analyzing trends in licensing and co-development deals

To View The Latest Industry Press Releases: http://www.marketresearchreports.biz/pressreleases

Frontier Pharma: Diabetic Complications – Innovative And Diverse Neuropathies, Nephropathy And Retinopathies Pipelines Demonstrate Shift Towards Disease Modifying Therapies

Worldwide Market studies the current scenario as well as future market potential of “Frontier Pharma: Diabetic Complications – Innovative And Diverse Neuropathies, Nephropathy And Retinopathies Pipelines Demonstrate Shift Towards Disease Modifying Therapies”

Diabetes is a common long-term condition that can lead to a range of disparate and serious complications. It is a lifelong, multi-systemic condition that affects a number of integral organs. Diabetes has a rapidly increasing prevalence – it currently affects 10% of adults globally, and is estimated to become the seventh-leading cause of death by 2030.

The lack of absolute treatment for the condition and the difficulty in maintaining constant glycemic control, even following adequate treatment, can result in a range of complications. The three main indication groups are diabetic nephropathy, which is a progressive condition caused by damage to the capillaries and kidneys glomeruli as a result of diabetes; diabetic retinopathy, which is defined as damage to the retina as a result of high blood sugar; and a range of diabetic neuropathies, a group of conditions in which nerve damage is caused as a result of diabetes mellitus.

The need for improved therapeutics within diabetic complications is especially prominent in comparison with other multi-systemic conditions, as the market is currently predominantly composed of therapies that symptomatically treat the condition, or at best slow disease progression. However, as the understanding of disease pathophysiology in both diabetes and its complications increases, new targets are being identified and converted into improved therapeutic options that are better aligned with the underlying disease pathophysiology than their predecessors.

The diabetic complications pipeline consists of 429 products that contain an array of targets not currently in use within the market. The increase in molecular target diversity signifies the high potential for changes and improvements in the diabetic complications market. One innovative therapy is CBX-129801, a promising synthetic peptide that is currently in development for diabetic neuropathy. Innovation can also be seen within diabetic retinopathy, with therapies such as BCN070660, a topical ophthalmologic formulation currently in development.

Scope

What effect do current market therapies have on disease progression?
Which drug classes dominate the current market?
What additional benefits have newly approved therapies brought to the market?
Can the increasing number of peptides in the pipeline prove useful in diabetic neuropathy?
Can neuroprotective therapies prove an important addition in diabetic retinopathies?
Can the diverse range of molecule types and molecular targets within the pipeline help reverse disease progression?
To what degree is the pipeline penetrated by first-in-class innovation?
What is the clinical potential of first-in-class products, based on their alignment to disease-causing pathways?
Which are the most promising first-in-class targets in early-stage development?
Which of the first-in-class products in development are not currently involved in a licensing or co-development deal, and therefore represent investment opportunities?

Reasons To Buy

Understand the current clinical and commercial landscape. It includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available.
Visualize the composition of the market for each diabetic complication individually, in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.
Analyze the pipeline for each diabetic complication individually and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking more innovative approaches to treating diabetic complications.
Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail.
Identify commercial opportunities in the diabetic complications deals landscape by analyzing trends in licensing and co-development deals and producing a curated list of diabetic complications therapies that are not yet involved in deals, and may be potential investment opportunities.

To View The Latest Industry Press Releases:http://www.marketresearchreports.biz/pressreleases

Global Market For Patient Engagement Solutions Industry Analysis and Forecast Driven By Rising Growth 2015

MarketResearchReports.Biz announces addition of new report “Global Patient Engagement Solutions Industry 2015 Market Research Report” to its database.

The Global Patient Engagement Solutions Industry 2015 Market Research Report is a professional and in-depth study on the current state of the Patient Engagement Solutions industry.

The report provides a basic overview of the industry including definitions and classifications. The Patient Engagement Solutions market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

The report focuses on global major leading industry players providing information such as company profiles, product specification, price, cost, revenue and contact information.

With 140 the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

To Get The Sample Copy Of This Report: http://www.marketresearchreports.biz/sample/sample/479356

Table of Contents

1 Industry Overview
1.1 Basic Information of Patient Engagement Solutions
1.1.1 Definition of Patient Engagement Solutions
1.1.2 Classifications of Patient Engagement Solutions
1.1.3 Applications of Patient Engagement Solutions
1.1.4 Characteristics of Patient Engagement Solutions
1.2 Development Overview of Patient Engagement Solutions
1.3 Enter Barriers Analysis of Patient Engagement Solutions

2 Patient Engagement Solutions International and China Market Analysis
2.1 Patient Engagement Solutions Industry International Market Analysis
2.1.1 Patient Engagement Solutions International Market Development History
2.1.2 Patient Engagement Solutions Competitive Landscape Analysis
2.1.3 Patient Engagement Solutions International Main Countries Development Status
2.1.4 Patient Engagement Solutions International Market Development Trend
2.2 Patient Engagement Solutions Industry China Market Analysis
2.2.1 Patient Engagement Solutions China Market Development History
2.2.2 Patient Engagement Solutions Competitive Landscape Analysis
2.2.3 Patient Engagement Solutions China Main Regions Development Status
2.2.4 Patient Engagement Solutions China Market Development Trend
2.3 Patient Engagement Solutions International and China Market Comparison Analysis

Click Here To Get More Reports By Pharmaceutical Market Research: http://www.marketresearchreports.biz/category/38

3 Environment Analysis of Patient Engagement Solutions
3.1 International Economy Analysis
3.2 China Economy Analysis
3.3 Policy Analysis of Patient Engagement Solutions
3.4 News Analysis of Patient Engagement Solutions

4 Analysis of Revenue by Classifications
4.1 Global Revenue of Patient Engagement Solutions by Classifications 2010-2015
4.2 Global Revenue Growth Rate of Patient Engagement Solutions by Classifications 2010-2015
4.3 Patient Engagement Solutions Revenue by Classifications

5 Analysis of Revenue by Regions and Applications
5.1 Global Revenue of Patient Engagement Solutions by Regions 2010-2015
5.2 2010-2015 USA Revenue and Revenue Growth Rate of Patient Engagement Solutions
5.3 2010-2015 Europe Revenue and Revenue Growth Rate of Patient Engagement Solutions
5.4 2010-2015 Japan Revenue and Revenue Growth Rate of Patient Engagement Solutions
5.5 2010-2015 China Revenue and Revenue Growth Rate of Patient Engagement Solutions

6 Analysis of Patient Engagement Solutions Revenue Market Status 2010-2015
6.1 Revenue of Patient Engagement Solutions 2010-2015
6.2 Revenue Market Share Analysis of Patient Engagement Solutions 2010-2015
6.3 Revenue Overview of Patient Engagement Solutions 2010-2015
6.4 Gross Margin of Patient Engagement Solutions 2010-2015

To View The Latest Industry Press Releases: http://www.marketresearchreports.biz/pressreleases

Global Psoriasis Market With Focus On Plaque Psoriasis: Outlook To 2020

MarketResearchReports.Biz announces the addition of a new report to its vast repository of research studies. The report is titled “Global Psoriasis Market With Focus On Plaque Psoriasis: Outlook To 2020”.

Psoriasis is a chronic inflammatory skin disease primarily causing scaling and inflammation of skin, characterized by sharply demarcated, scaly, red skin lesions most often on the elbows, knees, scalps, hands and feet. It occurs when the body’s immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis has been majorly classified into Plaque psoriasis, Guttate psoriasis, Inverse psoriasis, Pustular psoriasis and Erytherodermic psoriasis. It is an autoimmune disease and may be triggered by smoking, alcohol consumption, cold or dry weather and stress.

In the wake of lesser treatment options and costly therapies, psoriasis remains as an under treated disease. Psoriasis treatment can be divided into three main groups: topical treatment, light therapy, and systemic medication based on the severity of the disease. The typical treatment options include TNF inhibitors and IL inhibitors. However, various therapies and drugs are in the pipeline and it is expected that treatment options will improve over time with higher efficacy and lower costs.

The global market for psoriasis has been increasing consistently over the last few years. The major factors contributing to the growth of the global psoriasis market are increasing smoking and alcohol consumption trends globally. Surging smoking population, increased spending on medicines, increasing sales of prescription drugs and escalating health care expenditure are the key growth drivers of the market. However, growth of the market is hindered by extensive drug development and approval process and side-effects associated with the existing medication for psoriasis.

To Get The Sample Copy Of This Report: http://www.marketresearchreports.biz/sample/sample/748522

Various treatment methods are readily used to control psoriasis in the US, such as TNFs, systemics and topicals. With relatively higher prevalence rates in the US, several companies are trying to grab larger market shares with their new and innovative drugs. Plaque psoriasis is a common form of this disease in the US with increasing prevalence each year.

The report “Global Psoriasis Market” analyzes the development of this market, with focus on the US treatment market. The major trends, growth drivers as well as issues being faced by the market are discussed in detail in this report. The four major players: Johnson and Johnson, Abbvie inc., Amgen Inc. and Novartis are being profiled along with their key financials and strategies for growth.

Table of Content

1. Market Overview
1.1 Psoriasis
1.2 Types
1.2.1 Plaque Psoriasis
1.2.2 Guttate Psoriasis
1.2.3 Inverse Psoriasis
1.2.4 Pustular Psoriasis
1.2.5 Erytherodermic Psoriasis
1.3 Causes
1.4 Symptoms by Types
1.4.1 Plaque Psoriasis
1.4.2 Guttate Psoriasis
1.4.3 Inverse Psoriasis
1.4.4 Pustular Psoriasis
1.4.5 Erytherodermic Psoriasis
1.5 Diagnosis
1.6 Treatment Options
1.6.1 Topical Treatments
1.6.2 Light Therapy or Phototherapy
1.6.3 Systemic Treatments

Click Here To Get Pharmaceutical Market Research Reports: http://www.marketresearchreports.biz/category/38

2. Global Market
2.1 Global Psoriasis Market by Value
2.2 Global Psoriasis Market by Therapy

3. The US Market
3.1 Autoimmune Disease Market
3.1.1 The US Autoimmune Disease Market by Value
3.2 Psoriasis Market
3.2.1 The US Psoriasis Prevalence
3.2.2 The US Psoriasis Market by Value
3.2.3 The US Psoriasis Market by Treatment
3.2.4 The US Psoriasis IL-Inhibitors Market by Value
3.3 Plaque Psoriasis Market
3.3.1 The US Plaque Psoriasis Prevalence
3.3.2 The US Plaque Psoriasis Patients on Treatment
3.3.2 The US Plaque Psoriasis Biologics Market by Type

4. Market Dynamics
4.1 Growth Drivers
4.1.1 Surging Smoking Population
4.1.2 Increased Spending on Medicines
4.1.3 Increasing Sales of Prescription Drugs
4.1.4 Escalating Healthcare Expenditure
4.2 Key Trends
4.2.1 New Drugs against Psoriasis
4.2.2 Psoriasis Treatment Evolution
4.2.3 Key Pipeline Products in Conventional Therapies
4.2.4 Development of IL Based Treatments
4.2.5 Drug Development for Plaque Psoriasis
4.3 Challenges
4.3.1 Major Side-Effects of New Psoriasis Drugs
4.3.2 Extensive Drug Development and Approval Process

5. Competition
5.1 Global Market
5.1.1 Price Comparison of Key Biologic for Psoriasis
5.2 US Market
5.2.1 The US Psoriasis Biologics Revenue Comparison
5.2.1 The US Revenue Comparison per Patient for Psoriasis Drugs

6. Company Profiles
6.1 Johnson & Johnson
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Abbvie Inc.
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Amgen Inc.
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Novartis
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies

To View The Latest Industry Press Releases: http://www.marketresearchreports.biz/pressreleases

Rheumatoid Arthritis Market Treatment And Overviews- causes chronic inflammation of the joints

MarketResearchReports.Biz announces addition of new report “Global Rheumatoid Arthritis Market Report: 2016 Edition” to its database.

Arthritis means inflammation in a joint. Inflammation is a normal immune response in a body. It happens when the body, no longer has the ability to turn off the inflammatory response and thereby start damaging the healthy tissues of the body. This inflammation causes redness, warmth, swelling, and pain within the joint. There are more than 100 different types of arthritis, with different causes and treatment methods. Major classification of arthritis includes degenerative arthritis, inflammation arthritis, infectious and metabolic arthritis.

Rheumatoid arthritis or RA is classified under inflammatory arthritis. It is a chronic autoimmune disease. About 1 out of every 5 people who suffer from rheumatoid arthritis get lumps on their skin called rheumatoid nodules. This disease occurs in 4 main stages and can be diagnosed with certain blood tests, medical history, and imaging tests. There is no cure for rheumatoid arthritis, but there are various treatments available that reduce the pain like drugs, physical exercise or surgery.

The rheumatoid arthritis market is expected to grow in the coming years with growing demand for better medical facilities and more effective drugs. The US rheumatoid arthritis market dominates the global market with larger number of rheumatoid arthritis patients. The key trends of the market include increasing competition from anti-IL6 drugs, rising FDA approvals to RA drugs, use of complementary and alternative medicines, and increasing share of biosimilars.

To Get The Sample Copy Of This Report: http://www.marketresearchreports.biz/sample/sample/746067

The key factors driving the growth of the RA market includes increasing women population, escalating global ageing population, rising health care expenditure, rising cigarette consumption, and increasing obese population. However, there are certain factors which hinder the growth of the rheumatoid arthritis market like high cost of treatment and high research and development cost.

The report offers an in-depth analysis of the “Global Rheumatoid Arthritis Market” segmented into global and regional market. Competition is concentrated in the hands of few major pharmaceutical companies. Major RA companies that have been covered in the report include AbbVie, JNJ, Amgen Inc. and Pfizer Inc.